$EVAX

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

COPENHAGEN, Denmark, October 17, 2025 - Evaxion A/S ( NASDAQ: EVAX ) ( "Evaxion" ) , a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new two-year unprecedented clinical efficacy data of its personalized cancer vaccine EVX-01 in patients with ...

Original reporting
GlobeNewswire · Evaxion
Published Oct 17, 2025, 12:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 17, 2025, 1:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01 — source image
Decision brief

The 30-second read

$EVAXBullishHigh
01

Why it matters

The trial results could accelerate EVX-01's path to market, influencing investor sentiment and biotech valuations.

02

Market read

High relevance for biotech investors, especially those focused on immunotherapy and personalized cancer vaccines.

03

What to watch

Potential safety concerns or regulatory hurdles could delay commercialization, impacting stock performance.

Timing: short-term (next 1-3 months)

Background

Evaxion is developing AI-powered immunotherapies, with EVX-01 showing promising efficacy in early clinical trials.

Company-level read

Ticker impact

$EVAXBullishHigh confidence
Context

The news pertains directly to Evaxion's clinical trial results, indicating potential positive impact on its stock.

Expected impact

Moderate to strong upward movement in EVAX stock within the next 3-6 months, contingent on further clinical success and regulatory approval.

Evidence & confidence

The reported 75% objective response rate in a phase 2 trial is a strong efficacy indicator, likely to attract investor interest and drive stock price upward, assuming no adverse safety signals.

Market effects

Potential positive impact on biotech and immunotherapy sectors, with increased investor interest in innovative cancer treatments.

Primarily affects European biotech stocks, with possible spillover to global markets due to the significance of the trial results.

Moderate; advances in personalized cancer vaccines could influence global biotech investment trends.

Counterpoint

The positive trial data may be already priced in, and subsequent results could be disappointing, leading to volatility or decline.

Key entities

  • Evaxion

    A clinical-stage biotech specializing in AI-immunology vaccines.

Related articles

$ACIMed

Albertsons recalls ready-to-eat items in multiple states amid salmonella-linked jalapeño investigation

Albertsons Companies said it is voluntarily recalling four ready-to-eat products containing jalapeños supplied by Taylor Farms, including items sold at Randalls in Texas. The recall followed a supplier recall tied to an ongoing federal investigation and an FDA probe of a Salmonella Javiana outbreak. FDA reported 345 illnesses in 27 states, 36 hospitalizations, no deaths.

$CMGMed

Salmonella outbreak from Mexican jalapeños reported in 27 U.S. states

U.S. health authorities are investigating a Salmonella outbreak linked to Mexican jalapeño peppers. The CDC and FDA say 345 people are ill across 27 states, with 36 hospitalizations and no deaths. The supplier, Coast Citrus Distributors, recalled peppers sent to restaurants including Chipotle and QDOBA. Chipotle removed jalapeños from some outlets and shares fell over 8% on Aug. 4.

$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).